Mumbai-based Indian pharmaceutical MNC Lupin announced recently that its European hub entity, Lupin Atlantis Holdings SA, has successfully acquired two renowned brands, Aarane in Germany and Nalcrom in Canada and the Netherlands, as well as the associated trademark rights from Sanofi.

This strategic transaction complements Lupin's continuing efforts to increase its global presence in specialty areas. The acquisition will greatly improve Lupin's respiratory business in Germany, boosting the expansion of its newly developed franchise following the recent introduction of Luforbec. 

Nalcrom (sodium cromoglicate oral) belongs to the class of medications known as anti-allergics. Following extensive testing for sensitivity to specific allergens and a restriction of the primary allergens, it treats food allergies.

The chromone complex Aarane (sodium cromoglicate/reproterol hydrochloride pressurized inhalation) treats symptomatic acute asthma attacks brought on by allergies, exertion, stress, or infections. We also use it to prevent exercise-induced asthma or in situations where allergens are likely to be present.

Dr. Fabrice Egros, Lupin's President of Corporate Development, remarked on the acquisition, saying, "This acquisition will strengthen our global position in treating patients suffering from various respiratory diseases and conditions." It is a valuable asset to gastro-intestinal care, expanding our range of branded medicines. We are committed to delivering top-notch products and services to our clients and patients, enhancing the quality of life for millions of people globally.